Skip to Content

MiMedx Group, Inc.

Company NameMiMedx Group, Inc.
Stock SymbolMDXG

On December 29, 2023, after the market closed, MiMedx disclosed that it had received a warning letter from the U.S. Food and Drug Administration stating that the Company’s placental-derived tissue product, Axiofill, does not meet the requirements as a Section 361 product and is therefore subject to enforcement as a Section 351 product.

On this news, MiMedx’s stock price fell $0.90, or 10.3%, to close at $7.87 per share on January 2, 2024, thereby injuring investors.

Submit Your Information

If you suffered a loss on your MiMedx Group, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd